In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer

Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients who harbor activating EGFR mutations. However, the tumors of most patients initially sensitive to gefitinib will develop resistance within several mont...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Sha, Huanhuan, Dong, Shuchen, Yu, Chen, Zou, Renrui, Zhu, Yue, Lu, Ya, Zhang, Junying, Cao, Haixia, Chen, Dan, Wu, Jianzhong, Feng, Jifeng
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646187/
https://ncbi.nlm.nih.gov/pubmed/33193885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.46461
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados